Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 7/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044723 | 0.91 | PTK2 (0.33) | PTK2SCN9AKDRBRAFLRRK2 | |
| SCHEMBL13946764 | 0.91 | PTK2 (0.34) | PTK2SCN9AKDRBRAFLRRK2 | |
| SCHEMBL13044791 | 0.91 | PTK2 (0.34) | PTK2SCN9AKDRBRAFLRRK2 | |
| SCHEMBL13044794 | 0.91 | PTK2 (0.33) | PTK2SCN9AKDRBRAFLRRK2 | |
| SCHEMBL13044739 | 0.90 | SCN9A (0.34) | PTK2SCN9AKDR | |
| SCHEMBL13044756 | 0.90 | SCN9A (0.34) | PTK2SCN9AKDR | |
| SCHEMBL13044704 | 0.89 | SCN9A (0.35) | PTK2SCN9AKDRBRAF | |
| SCHEMBL13044819 | 0.89 | PTK2 (0.34) | PTK2SCN9AKDRLRRK2 | |
| SCHEMBL13044742 | 0.89 | SCN9A (0.35) | PTK2SCN9AKDRLRRK2 | |
| SCHEMBL13044814 | 0.88 | SCN9A (0.33) | PTK2SCN9AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009018656-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |